Encompass Health Corp (EHC) Stock Analysis and Metrics

Encompass Health

NYSE: EHC

$112.22 ▼ -0.26 (-0.24%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap10.07 Bn

P/E654.20

P/S1.66

Div. Yield0.01

ROIC (Qtr)0.00

Total Debt (Qtr)2.57 Bn

Revenue Growth (1y) (Qtr)9.01

Add ratio to table…

About

Encompass Health Corp is the nation’s largest owner and operator of inpatient rehabilitation hospitals. The company provides specialized rehabilitative treatment using advanced technology and intensive therapy on an inpatient basis for patients recovering from a major injury or illness who seek to regain functional ability independence and quality of life. It operates hospitals in 39 states and Puerto Rico with concentrations in Florida and Texas. As of December 31 2025 Encompass Health Corp operated 173 inpatient rehabilitation hospitals containing 11,465 licensed beds. The company is committed to delivering high quality cost effective patient care. In 2025 it was named America’s Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista and ranked among Fortune’s World’s Most Admired Companies and Forbes’ Most Trusted Companies in America.

Encompass Health Corp generates revenue primarily from payments for patient care services received from federal and state government programs and private insurers. In 2025 inpatient rehabilitation services produced $5,756.3 million of net operating revenues while other sources contributed $178.9 million for a total of $5,935.2 million. The payer mix shows Medicare accounting for 65.4% of revenues Medicare Advantage for 16.4% managed care for 10.7% Medicaid for 3.1% other third party payors for 0.7% Workers' compensation for 0.5% patients for 0.3% and other income for 2.9%. Revenues are generated under the Medicare inpatient rehabilitation prospective payment system which pays a fixed amount per discharge based on patient case mix and under negotiated rates with private insurers and public programs.

Encompass Health Corp holds a leading position in the inpatient rehabilitation industry as the largest owner and operator of such hospitals by patients treated revenues and number of facilities. Its competitive advantages arise from strong clinical outcomes cost effectiveness financial strength and extensive application of technology. The company differentiates itself through a culture focused on quality a disciplined operating model and scale that enables data driven process improvements. Competitors mainly consist of rehabilitation units located within acute care hospitals numerous privately held providers and one public company that operates 38 inpatient rehabilitation hospitals across the United States. Nursing homes that offer limited rehabilitation services also compete for some patients. The company’s size its focus on evidence based protocols and its ability to adapt to regulatory changes help it maintain its market standing.

Encompass Health Corp serves patients who are admitted to its hospitals following physician referrals from acute care hospitals. Approximately 92% of its patients come from acute care settings after experiencing conditions such as strokes hip fractures traumatic brain injuries spinal cord injuries or other neurological disorders that require intensive rehabilitation therapy. The majority of patients are Medicare beneficiaries aged 65 and older with an average age of about 77. The payer mix includes Medicare Medicare Advantage managed care plans Medicaid Workers' compensation and other third party payors as well as direct patient payments. Demographic trends indicate that the population aged 75 and older is expected to grow at roughly 4% per year through 2030 supporting long term demand for the company’s services. Specific customer names are not disclosed in the filing but the base comprises individual patients and the various insurance and government programs that reimburse for rehabilitation care.

Investment Thesis

▲ Bull case

Encompass Health is strategically leveraging its small-format hospital initiative to unlock growth in high-occupancy, landlocked markets where traditional bed expansions face permitting and construction delays, with plans to open at least one facility in 2027 and a pipeline evaluating dozens of additional sites, which will allow the company to capture incremental demand without the capital intensity or regulatory hurdles of full-scale de novos, as evidenced by the recent land acquisition in Haslet, Texas for a 50-bed facility and the announcement of a 36-bed freestanding hospital in Bridgeport, West Virginia, demonstrating execution on this flexible growth model that shares administrative services and Medicare provider numbers with existing hospitals to optimize operational efficiency and accelerate time-to-market.
The company's "admit and appeal" strategy for Medicare Advantage denials, currently piloted in nine hospitals, is showing early positive results in claim approval rates and represents a materially underappreciated catalyst for improving MA reimbursement dynamics, particularly given that MA penetration has peaked at ~52% and is declining in key markets, shifting volume toward more favorable fee-for-service patients while simultaneously enhancing capture rates within the existing MA population through persistent appeals, with management noting the strategy is still too early for definitive conclusions but expressing encouragement from initial traction, suggesting upside potential as the program scales and data matures over the next 12-18 months.
Encompass Health is benefiting from a structural shift in Medicaid funding through state-directed payment programs, which have transformed previously unprofitable markets into EBITDA-accretive opportunities, with approximately 20% of its markets now in states offering attractive supplemental payment structures that, when combined with base IRF reimbursement, create profitable patient economics—a trend underscored by the $4.2 million out-of-period EBITDA benefit recognized in Q1 and the full-year guidance assuming a flat $21 million impact, indicating sustainable and growing support from state Medicaid programs that are increasingly recognizing the value of IRF services in reducing downstream acute care costs.
The company's partnership with Palantir is driving under-the-radar operational efficiencies across real estate analysis, revenue cycle management, clinical staffing, and documentation streamlining, with specific initiatives like prescreen narratives and appeal letters already freeing up clinical staff time for direct patient care, which—combined with the lowest RN turnover rate since at least 2012 (17.8% annualized) and a mere 2.6% turnover for nurses on clinical ladders versus 20.7% for non-laddered staff—creates a self-reinforcing cycle of labor efficiency, reduced premium labor spend (down 9.4% YoY), and enhanced capacity to serve high-acuity patients without proportional cost increases, positioning EHC to expand margins even as it scales capacity through its aggressive bed addition and hospital development pipeline.
Despite near-term headwinds from unit closures impacting same-store discharge growth by approximately 85 basis points, Encompass Health is effectively consolidating displaced volume into proximate hospitals and adding beds in affected markets (e.g., 40 beds in Evansville, Indiana), with management confirming that the EBITDA impact of these closures is neutral and the long-term growth trajectory remains intact, supported by a robust pipeline of 11 new hospitals with 520 beds beyond 2026, 18 IRF development projects underway (including joint ventures), and a capital expenditure outlook that will peak at 15% of revenue over the next two to three years before normalizing to 10%-12%, indicating disciplined, high-return reinvestment that will drive sustained discharge growth and free cash flow generation well into the future.

Encompass Health is strategically leveraging its small-format hospital initiative to unlock growth in high-occupancy, landlocked markets where traditional bed expansions face permitting and construction delays, with plans to open at least one facility in 2027 and a pipeline evaluating dozens of additional sites, which will allow the company to capture incremental demand without the capital intensity or regulatory hurdles of full-scale de novos, as evidenced by the recent land acquisition in Haslet, Texas for a 50-bed facility and the announcement of a 36-bed freestanding hospital in Bridgeport, West Virginia, demonstrating execution on this flexible growth model that shares administrative services and Medicare provider numbers with existing hospitals to optimize operational efficiency and accelerate time-to-market.
The company's "admit and appeal" strategy for Medicare Advantage denials, currently piloted in nine hospitals, is showing early positive results in claim approval rates and represents a materially underappreciated catalyst for improving MA reimbursement dynamics, particularly given that MA penetration has peaked at ~52% and is declining in key markets, shifting volume toward more favorable fee-for-service patients while simultaneously enhancing capture rates within the existing MA population through persistent appeals, with management noting the strategy is still too early for definitive conclusions but expressing encouragement from initial traction, suggesting upside potential as the program scales and data matures over the next 12-18 months.
Encompass Health is benefiting from a structural shift in Medicaid funding through state-directed payment programs, which have transformed previously unprofitable markets into EBITDA-accretive opportunities, with approximately 20% of its markets now in states offering attractive supplemental payment structures that, when combined with base IRF reimbursement, create profitable patient economics—a trend underscored by the $4.2 million out-of-period EBITDA benefit recognized in Q1 and the full-year guidance assuming a flat $21 million impact, indicating sustainable and growing support from state Medicaid programs that are increasingly recognizing the value of IRF services in reducing downstream acute care costs.
The company's partnership with Palantir is driving under-the-radar operational efficiencies across real estate analysis, revenue cycle management, clinical staffing, and documentation streamlining, with specific initiatives like prescreen narratives and appeal letters already freeing up clinical staff time for direct patient care, which—combined with the lowest RN turnover rate since at least 2012 (17.8% annualized) and a mere 2.6% turnover for nurses on clinical ladders versus 20.7% for non-laddered staff—creates a self-reinforcing cycle of labor efficiency, reduced premium labor spend (down 9.4% YoY), and enhanced capacity to serve high-acuity patients without proportional cost increases, positioning EHC to expand margins even as it scales capacity through its aggressive bed addition and hospital development pipeline.
Despite near-term headwinds from unit closures impacting same-store discharge growth by approximately 85 basis points, Encompass Health is effectively consolidating displaced volume into proximate hospitals and adding beds in affected markets (e.g., 40 beds in Evansville, Indiana), with management confirming that the EBITDA impact of these closures is neutral and the long-term growth trajectory remains intact, supported by a robust pipeline of 11 new hospitals with 520 beds beyond 2026, 18 IRF development projects underway (including joint ventures), and a capital expenditure outlook that will peak at 15% of revenue over the next two to three years before normalizing to 10%-12%, indicating disciplined, high-return reinvestment that will drive sustained discharge growth and free cash flow generation well into the future.

▼ Bear case

Encompass Health's Medicare Advantage mix remains a persistent structural headwind, with MA penetration having peaked at roughly 52% and now declining in 20 states and 31% of its home counties, creating a volume drag that management acknowledges is not being fully offset by the nascent "admit and appeal" strategy—still limited to nine hospitals and described as "way too early" for definitive conclusions—while the net revenue gap between MA and FFS has narrowed to just 1%, suggesting that even with higher acuity concentration in MA admits, the company is not achieving meaningful pricing leverage, and the ongoing reliance on MA patients exposes EHC to utilization management risks from private payors that could intensify if MA plans implement stricter prior authorization or site-of-care steered networks.
The company's aggressive capacity expansion plan, with CapEx expected to peak at 15% of revenue over the next two to three years, carries significant execution risk given the lengthy permitting and construction lead times explicitly cited by management as reasons for lowering the internal bed expansion occupancy threshold from 80%-85% to 70%-75%, and while the small-format hospital model aims to mitigate this, the strategy remains unproven at scale, with no clear timeline for ROI validation and potential for overbuilding in markets where demand growth may not sustain the elevated occupancy assumptions embedded in the pipeline of seven new hospitals (340 beds) and 100-150 additional bed additions within the year, let alone the eleven hospitals with 520 beds planned beyond 2026.
Encompass Health's labor cost advantages, while highlighted by declining premium labor spend and improved RN turnover, are vulnerable to wage inflation and unionization pressures in a highly competitive healthcare labor market, particularly as the company increases reliance on career ladder programs that drive higher compensation levels—Q1 SWB per FTE rose 3.7% due to increased participation in these programs—and with contract labor FTEs already at a low 1.2%, there is limited room for further premium labor cost reduction, leaving the company exposed to rising base wages that could erode EBITDA margins if reimbursement growth from the CMS proposed rule (estimated 2.4% Medicare pricing increase effective October 1, 2026) fails to keep pace with labor inflation, especially given that management is not targeting further reductions in length of stay (averaging 12 days) as a lever for operational efficiency.
The recent debt refinancing activity—including the $500 million private offering of 5.875% senior notes due 2034 to redeem $400 million of 4.500% notes due 2028 and repay $100 million of revolving credit facility—while improving the maturity profile, increases annual interest expense by approximately $5 million (as noted in Q1) and locks in higher financing costs in a rising rate environment, with the company acknowledging that the free cash flow guidance revision was partially driven by this upward interest expense adjustment, and although net leverage remains low at 1.9x, the increased debt burden reduces flexibility for future share repurchases or acquisitions if operating performance falters, particularly given the $71.6 million spent on buybacks in Q1 and the reliance on free cash flow to fund both growth CapEx and shareholder returns.
Encompass Health's outpatient services, which showed year-over-year volume growth for the first time in recent years, remain a non-core focus and are subject to ongoing profitability review, with management explicitly stating that outpatient clinics are "not a core business" and will continue to be evaluated for potential further reduction in count, indicating that any near-term outpatient volume strength is likely transitional and not a sustainable growth driver, while the company's continued investment in expensive inpatient capacity (e.g., 50-bed hospitals in Haslet, Texas; Bridgeport, West Virginia; Concordville, Pennsylvania; and Post Falls, Idaho) risks overextension if referral volumes from acute care partners do not materialize as expected, especially in markets where the company is expanding despite occupancy constraints that have already prompted a strategic shift toward small-format solutions.

Encompass Health's Medicare Advantage mix remains a persistent structural headwind, with MA penetration having peaked at roughly 52% and now declining in 20 states and 31% of its home counties, creating a volume drag that management acknowledges is not being fully offset by the nascent "admit and appeal" strategy—still limited to nine hospitals and described as "way too early" for definitive conclusions—while the net revenue gap between MA and FFS has narrowed to just 1%, suggesting that even with higher acuity concentration in MA admits, the company is not achieving meaningful pricing leverage, and the ongoing reliance on MA patients exposes EHC to utilization management risks from private payors that could intensify if MA plans implement stricter prior authorization or site-of-care steered networks.
The company's aggressive capacity expansion plan, with CapEx expected to peak at 15% of revenue over the next two to three years, carries significant execution risk given the lengthy permitting and construction lead times explicitly cited by management as reasons for lowering the internal bed expansion occupancy threshold from 80%-85% to 70%-75%, and while the small-format hospital model aims to mitigate this, the strategy remains unproven at scale, with no clear timeline for ROI validation and potential for overbuilding in markets where demand growth may not sustain the elevated occupancy assumptions embedded in the pipeline of seven new hospitals (340 beds) and 100-150 additional bed additions within the year, let alone the eleven hospitals with 520 beds planned beyond 2026.
Encompass Health's labor cost advantages, while highlighted by declining premium labor spend and improved RN turnover, are vulnerable to wage inflation and unionization pressures in a highly competitive healthcare labor market, particularly as the company increases reliance on career ladder programs that drive higher compensation levels—Q1 SWB per FTE rose 3.7% due to increased participation in these programs—and with contract labor FTEs already at a low 1.2%, there is limited room for further premium labor cost reduction, leaving the company exposed to rising base wages that could erode EBITDA margins if reimbursement growth from the CMS proposed rule (estimated 2.4% Medicare pricing increase effective October 1, 2026) fails to keep pace with labor inflation, especially given that management is not targeting further reductions in length of stay (averaging 12 days) as a lever for operational efficiency.
The recent debt refinancing activity—including the $500 million private offering of 5.875% senior notes due 2034 to redeem $400 million of 4.500% notes due 2028 and repay $100 million of revolving credit facility—while improving the maturity profile, increases annual interest expense by approximately $5 million (as noted in Q1) and locks in higher financing costs in a rising rate environment, with the company acknowledging that the free cash flow guidance revision was partially driven by this upward interest expense adjustment, and although net leverage remains low at 1.9x, the increased debt burden reduces flexibility for future share repurchases or acquisitions if operating performance falters, particularly given the $71.6 million spent on buybacks in Q1 and the reliance on free cash flow to fund both growth CapEx and shareholder returns.
Encompass Health's outpatient services, which showed year-over-year volume growth for the first time in recent years, remain a non-core focus and are subject to ongoing profitability review, with management explicitly stating that outpatient clinics are "not a core business" and will continue to be evaluated for potential further reduction in count, indicating that any near-term outpatient volume strength is likely transitional and not a sustainable growth driver, while the company's continued investment in expensive inpatient capacity (e.g., 50-bed hospitals in Haslet, Texas; Bridgeport, West Virginia; Concordville, Pennsylvania; and Post Falls, Idaho) risks overextension if referral volumes from acute care partners do not materialize as expected, especially in markets where the company is expanding despite occupancy constraints that have already prompted a strategic shift toward small-format solutions.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password